What do we know about the macular pigment in AMD: the past, the present, and the future

被引:64
作者
Arunkumar, Ranganathan [1 ]
Calvo, Charles M. [1 ]
Conrady, Christopher D. [1 ]
Bernstein, Paul S. [1 ]
机构
[1] Univ Utah, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84112 USA
关键词
HETEROCHROMATIC FLICKER PHOTOMETRY; MESO-ZEAXANTHIN; BETA-CAROTENE; OPTICAL-DENSITY; EYE DISEASE; INTESTINAL-ABSORPTION; RETINAL ACCUMULATION; CONTRAST SENSITIVITY; DIETARY CAROTENOIDS; EPITHELIAL-CELLS;
D O I
10.1038/s41433-018-0044-0
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Carotenoids are lipophilic isoprenoid pigments with a common C40H56 core chemical structure that are naturally synthesized by many plants, algae, bacteria, and fungi. Humans and animals cannot synthesize carotenoids de novo and must obtain them solely through dietary sources. Among the more than 750 carotenoids in nature, only lutein, zeaxanthin, meso-zeaxanthin, and their oxidative metabolites selectively accumulate in the foveal region of the retina where they are collectively referred to as the macular pigment (MP) of the macula lutea. MP serves an ocular protective role through its ability to filter phototoxic blue light radiation and also via its antioxidant activity. These properties have led to the hypothesis that carotenoids may protect against the development of age-related macular degeneration (AMD), the most common cause of blindness in the aged population >60 years old. Epidemiological studies have supported this by showing that patients with lower concentrations of serum carotenoids and macular pigment optical density (MPOD) measurements are at a higher risk of developing AMD. Conversely, nutritional supplementation and diets rich in lutein and zeaxanthin readily impact MP concentrations and reduce the risk of progression to advanced AMD, and the AREDS2 supplement formulation containing 10 mg of lutein and 2 mg of zeaxanthin is the standard-of-care recommendation for individuals at risk for visual loss from advanced AMD. This article reviews the rich history of research on the MP dating back to the 1700s and outlines their potential for further therapeutic improvements for AMD in the future.
引用
收藏
页码:992 / 1004
页数:13
相关论文
共 98 条
[11]  
Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
[12]   Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients [J].
Bernstein, PS ;
Zhao, DY ;
Wintch, SW ;
Ermakov, IV ;
McClane, RW ;
Gellermann, W .
OPHTHALMOLOGY, 2002, 109 (10) :1780-1787
[13]   Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye [J].
Bernstein, PS ;
Khachik, F ;
Carvalho, LS ;
Muir, GJ ;
Zhao, DY ;
Katz, NB .
EXPERIMENTAL EYE RESEARCH, 2001, 72 (03) :215-223
[14]   Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) as a zeaxanthin-binding protein in the macula of the human eye [J].
Bhosale, P ;
Larson, AJ ;
Frederick, JM ;
Southwick, K ;
Thulin, CD ;
Bernstein, PS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :49447-49454
[15]   Identification and metabolic transformations of carotenoids in ocular tissues of the japanese quail Coturnix japonica [J].
Bhosale, Prakash ;
Serban, Bogdan ;
Zhao, Da You ;
Bernstein, Paul S. .
BIOCHEMISTRY, 2007, 46 (31) :9050-9057
[16]   PRELIMINARY IDENTIFICATION OF THE HUMAN MACULAR PIGMENT [J].
BONE, RA ;
LANDRUM, JT ;
TARSIS, SL .
VISION RESEARCH, 1985, 25 (11) :1531-1535
[17]  
BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
[18]  
BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
[19]   Genetic variants in BCMO1 and CD36 are associated with plasma lutein concentrations and macular pigment optical density in humans [J].
Borel, Patrick ;
de Edelenyi, Fabien Szabo ;
Vincent-Baudry, Stephanie ;
Malezet-Desmoulin, Christiane ;
Margotat, Alain ;
Lyan, Bernard ;
Gorrand, Jean-Marie ;
Meunier, Nathalie ;
Drouault-Holowacz, Sophie ;
Bieuvelet, Severine .
ANNALS OF MEDICINE, 2011, 43 (01) :47-59
[20]  
Buzzi F, 1782, NUOVE SPERIENZE FATT